

The logo for TWIST BIOSCIENCE features the word "TWIST" in large, white, uppercase letters. Below it, the word "BIOSCIENCE" is written in a smaller, teal, uppercase font. The text is flanked by several teal dots of varying sizes, some arranged in a semi-circle above and below the letters.

TWIST  
BIOSCIENCE

The background is a dark teal color. On the left side, there are several curved lines of glowing teal dots that appear to be part of a larger structure. On the right side, there is a faint, wireframe-like representation of a protein structure, showing various folds and helices.

# WRITING THE FUTURE

JUNE 2026

# LEGAL DISCLAIMER

This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements labeled 'FY 2026 Guidance', regarding future growth and expansion, estimated turnaround times, drivers of future revenue and gross margin growth, market size and growth, estimated annual fiscal 2026 revenues, ability and timing to achieve profitability, ability and timing to achieve adjusted EBITDA breakeven and ability to maintain or increase gross margins and Twist's other expectations regarding its future operations plans and financial performance, introduction of new products, and newly announced partnerships. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or noncompetitive; the ability to integrate and leverage artificial intelligence and machine learning technologies to improve operational efficiency, product development, and customer solutions; the ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; the ability to maintain and enforce intellectual property protection; uncertainty as to economic and market conditions and the impact of adverse economic conditions; and the ability to obtain financing when necessary. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K filed with the SEC on November 17, 2025. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

The presentation also contains supplemental financial information determined by methods other than in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP measure are not in accordance with, or an alternative for, measures prepared in accordance with generally accepted accounting principles (GAAP) and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. A reconciliation of these non-GAAP financial measures may be found starting on page 35 of this presentation.

A reconciliation of adjusted EBITDA for the fourth quarter of fiscal 2026 to a corresponding GAAP financial guidance measure is not available on a forward-looking basis because the Company does not provide guidance on GAAP net loss and is not able to present the various reconciling cash and non-cash items between GAAP net loss and adjusted EBITDA without unreasonable effort. In particular, stock-based compensation expense is impacted by the Company's future hiring and retention needs, as well as the future fair market value of its common stock, all of which are difficult to predict and are subject to change. The actual amount of these expenses during fiscal 2026 will have a significant impact on Twist's future GAAP financial results.



# Twist Bioscience

## Customizable Solutions Powering the Biological Continuum

Proprietary Silicon-  
Based DNA  
Synthesis Platform

~\$377M  
Revenue  
(FY 2025)

**Enabling**  
Therapeutics, Diagnostics, Industrial,  
Research, Ag and Applied Markets

\$442 - \$447M  
Guided FY26 Revenue  
(May 4, 2026)

~1,000  
Employees

**MULTI-BILLION \$**  
Growing Markets

### Established Global Footprint, Capacity for Growth



# DIVERSE SOLUTIONS, MANY APPLICATIONS

## DNA SYNTHESIS & PROTEIN SOLUTIONS

Powering the Design-Build-Test-Learn Cycle for Early-stage Biotech through Big Pharma, Large Tech and Academic Research  
(Formerly SynBio and Biopharma)

## NGS APPLICATIONS\*

Enabling Efficient and Effective Customized, Scalable Solutions for Cancer, Inherited and Rare Disease Diagnostics  
(Formerly NGS)



**THERAPEUTICS**  
Health



**CHEMICALS**  
Sustainability



**DIAGNOSTICS**  
Precision Medicine



**FOOD**  
Food Security



# > 3,800 CUSTOMERS ACROSS INDUSTRIES RELY ON TWIST

32 of the top 34

**Diagnostics  
Companies**

(by analyst tracking list)

19 of the top 20

**Pharma  
Companies**

(by 2024 revenue)

21 of the top 30

**Top Biotech  
Companies**

(by NYSE Biotech Index Fund)

41 of the top 50

**Top Worldwide  
Universities**

(by US News)



**We Enable Innovation**

**Accelerating Discovery, Improving Performance, and Reducing Risk at Attractive Economics**



# WE CONTINUE LOADING **MORE** ON THE **SAME** CHIP

Rapid Growth, Unmatched Scale, High Margin Expansion


DNA on Silicon Platform

**MORE**  
Products

**MORE**  
Customers


**MORE**  
Applications

**MORE**  
Markets




T W I S T  
BIO SCIENCE

# Synergistic Solutions that Work Together




## NGS applications

## DNA synthesis & protein solutions




# CONTINUING TO ITERATE AND IMPROVE PROPRIETARY PLATFORM

- Continuing low error rate with improved **consistency**
- Continue to **reduce reagent cost** and **chemical waste**
- Faster synthesis **increases writer capacity**, enhances products, and expands throughput
- Enables **new product introductions**




Cost  
(\$)




~60%  
reduction  
in cost

Waste  
(Liter)



~70%  
reduction  
in waste


TAT  
(Hr)



~73%  
reduction  
in TAT  
~4x increase  
in capacity


# AUTOMATED FROM START TO FINISH

## Automate key bottleneck steps




### Oligo Fragment System

Hands-off oligo to linearized DNA workflow



### Colony Picker System

Automated inoculation for three scales of media growth



### NGS Prep System

Automated workflow for sample to ready-to-sequence libraries



### Miniprep System

Automated workflow for purified plasmid DNA


Building scalable process so that **multiple processes can run on the same tools** (e.g. complexity process with minimum addition of equipment)

## Enable scaling with more integrated systems


Number of integrated systems

● NGS panels and kits

● DNA synthesis and protein solutions



# AUTOMATING THE AUTOMATION: DOUBLING THROUGHPUT IN 20% OF PHYSICAL FOOTPRINT



**Then**  
**Gene fragment workstation**  
**(step 1 and step 2)**  
 ~950 sq.ft. + ~950 sq.ft.

**Now**  
**2 integrated systems**  
**System 1** + **System 2**  
 ~150 sq.ft. + ~160 sq.ft.


	Automated	Integrated
# of operators	3-4	1-2
Hands-on time (hours)	9-10	1-2
Batch size	12 plates	16 plates
Tracking steps	50% reduction in integrated	

Now, we are manufacturing  
**2x gene fragments in**  
**1/5 the space**

We “automated the automation”

- ↑ Increased capacity
- ↑ Increased productivity
- ↓ Reduced headcount required


# IN PURSUIT OF SPEED: DECREASED TAT OVER TIME



# 2030: CONTINUING TO EXPAND SAMs DRIVEN BY NPIS

**\$6B SAM\* and >\$90B TAM**


NGS Applications



\*Liquid biopsy (therapy selection, multicancer screening, minimal residual disease), comprehensive genomic profiling tissue  
 \*\*BCC reports, DeciBio, Twist internal estimates


**\$7B+ SAM\* and \$18B TAM**

DNA Synthesis and Protein Solutions



\*BCC reports, DeciBio, Grand View, Antibodies – recombinant protein market stat; Twist internal estimates

# MULTIPLE GROWTH LEVERS – H1FY2026 TO H1FY2025



## SUPERIOR SOLUTIONS

- No need to compromise on precision, scale, or value
- Hundreds of SKUs for diverse applications
- Frictionless e-commerce

## EXCEPTIONAL CUSTOMER EXPERIENCE

- Customized solutions for a range of needs
- Excellent experience at every level
- Meet every challenge head on

# Our Powerful Advantages

## OPERATIONAL EXCELLENCE

- Automation for efficiency, quality and rapid delivery
- Broad and deep scientific expertise
- ISO 13485 certification in all manufacturing locations

## FINANCIAL DISCIPLINE

- Adjusted EBITDA\* breakeven for Q4 FY 26
- Prioritized investments in innovation
- Gross margin > 50%\*\*
- Targeted capital allocation



# PROFITABLE GROWTH IS IN SIGHT

**Sustained** revenue and margin growth

**Continued** operational and commercial execution

**New** products and **AI offering**

Investment in innovation driving **top line acceleration**

**Growing** markets and customers



T W I S T  
BIOSCIENCE

**Adjusted  
EBITDA Breakeven**


**Q4 FY 2026**

# PROVEN COMMERCIAL EXECUTION, FINANCIAL DISCIPLINE



## Annual Revenue

\$ Millions



<b>Adjusted OpEx*</b>	\$126M	\$164M	\$248M	\$260M	\$253M	\$262M
<b>Adjusted EBITDA**</b>	(\$93.8M)	(\$106.5M)	(\$152.8M)	(\$147.3M)	(\$93.6M)	(\$46.9M)

\* Adjusted OpEx is defined as SG&A and R&D expenses excluding depreciation and amortization and stock-based compensation expense. See adjusted OpEx reconciliation on page 37

\*\* See page 36 for Adjusted EBITDA Reconciliation


\*\*\*Guidance as of May 4, 2026

**33% CAGR**  
over last 6 years

**20% points**  
margin improvement


**Diversified**  
revenue base

# 13 CONSECUTIVE QUARTERS OF SEQUENTIAL REVENUE GROWTH




# NEW INDUSTRY REVENUE REPORTING (FY25 Comp)


**LEGACY**  
Industry  
Reporting  
FY25  
% change vs. PY



**NEW**  
Industry  
Reporting  
FY25  
% change vs. PY



# 2QFY26 INDUSTRY REVENUE REPORTING



~75% of global supply partner revenue is **NGS Applications**, largely **Diagnostics**

# ATTRACTIVE, PROFITABLE RESALE & DISTRIBUTOR MODELS

## Resale

18

Global Life Science  
Tools Companies Buy from Twist

- Customers resell our DNA under their brand
- Incremental opportunities to “fill the chip”
- Highly sticky, cost-efficient business

## Distributors

Distributors & Channel  
Partners



- Capital efficient way to cultivate future direct customers
- Minimal sales and marketing spend

## DNA SYNTHESIS & PROTEIN SOLUTIONS

Powering the Design-Build-Test-Learn  
Cycle for Early-stage Biotech through  
Big Pharma, Academic Research

**\$53.3M** Revenue 2QFY26

**28%** YoY Growth

**4%** QoQ Growth

# DNA SYNTHESIS & PROTEIN SOLUTIONS

## PRODUCTS

Speed

Cost

Scale

Quality

Frictionless  
eCommerce

Why  
We Win

One stop shop  
for discovery optimization

Robust AI and data for the  
**entire workflow**

## ANTIBODY SERVICES




## PRODUCTS

- Clonal genes
- Express genes
- Gene fragments\*
- MGF\*
- Characterization\*
- Oligo pools
- Variant libraries

## ANTIBODY SERVICES

- Discovery
- Developability
- Functionality
- Accessibility
- Characterization\*


### Frontier AI Lab



**AI Enabled  
Discovery**


**Different Approach**  
for Every Customer  
All Adding IgG/Characterization

### Large Pharma




- Biopharma Services
- Gene Fragments
- Other
- Custom Vector Onboarding
- Multiplexed Gene Fragments
- Custom Panel
- Libraries
- Custom Production
- Library Prep
- Clonal Genes
- Kits and Reagents
- IgG+ Characterization
- Fixed Panel
- Oligo Pools


### Large Pharma



### AI-Native Biotech



### Dry Lab Biotech



\* Revenue charts not presented on uniform scale

# AI HAS OPENED NEW DOORS FOR GROWTH

AI Amplifies the Value of Our Technology

## Traditional Therapeutics Companies

We sell products and data  
(Wet lab model)

**\$25M** of **\$66M**

FY2025 order growth was  
**for AI drug discovery**

On track for triple  
digit growth  
in FY26

## AI & Tech Companies


We sell data  
(Dry lab model)

WE ARE THE MARKET LEADER

DNA on Silicon **PLATFORM**, unmatched **SCALE**, and rapid **TURNAROUND**

# ONE PLATFORM, MANY TAILORED SOLUTIONS

Meeting customers where they are, supporting them as ambitions grow



Purpose-built for cost effective synthesis of **100s to 1,000s** of unique sequences in parallel

## NGS APPLICATIONS\*

Enabling Efficient and Effective Customized,  
Scalable Solutions for Cancer, Inherited and Rare  
Disease Diagnostics

**\$57.4M** Revenue 2QFY26

**12%** YoY Growth\*  
**9%** QoQ Growth

# NGS APPLICATIONS

## PRODUCTS

Quality

Uniformity and lower sequencing cost

Comprehensive workflows

Rapid customization

Fast throughput

Sequencer agnostic

Why We Win

NGS **20,000 samples per day**  
(Gene production)

Deep NGS **expertise and at cost** consumables

Strong **pharma partnerships** who outsource NGS

## SERVICES

T W I S T  
BIOSCIENCE

## PRODUCTS


- Fixed panels
- Custom panels
- Alliance panels
- Library prep kits
- Reagents
- Controls and standards

## SERVICES

- Pre and post-sale application support
- Bioinformatics
- Automation
- Service Lab\*
- Pilot Lab

# Growing with our customers as they move from R&D to production


EXPANDING  
ORDER VOLUME




## Common Pattern Across Product Lines

✓ MRD	✓ LIQUID BIOPSY	✓ RARE DISEASE	✓ THERAPY SELECTION
✓ CGP	✓ NIPT	✓ AGRIGENOMICS	✓ POPULATION GENETICS

### TUMOR INFORMED MRD CUSTOMER




### ONCOLOGY DIAGNOSTICS CUSTOMER, MULTIPLE TESTS




Expanding Order Volume  
Customer Revenue (\$)

### RARE DISEASE CUSTOMER




### ONCOLOGY DIAGNOSTICS CUSTOMER



■ Custom Panel   
 ■ Fixed Panel   
 ■ Kits and Reagents   
 ■ Library Prep   
 ■ Other



# Twist Powers the Continuum of Care in Cancer Research



## DIAGNOSTIC

## THERAPEUTIC

### SCREENING

### EARLY DETECTION + PROFILING

### MINIMAL RESIDUAL DISEASE

### NEOANTIGEN THERAPY

WGS + WES  
High throughput applications

RNA-Seq  
Low input, FFPE, Whole transcriptome

WGS + WES  
High throughput applications

Methylation  
Epigenetic biomarker detection

Express MRD  
1 BD TAT personalized panels

WGS + WES  
High throughput applications

Library Prep + Enrichment

Custom Panels (HLA)  
Multi-allelic coverage

Liquid Biopsy  
Deep sequencing applications

CGP Panels  
Oncology detection

Custom Panels  
Targeted tumor naïve tests

cfDNA LP  
Ultra sensitive library preparation

mRNA

Clonal Genes

Antibody Discovery

HT IgG

# LOADING MORE ON THE SAME CHIP


## Future Innovation

### MORE Products

- mRNA / complexity
- MRD Express
- siRNA - ASO Discovery

### MORE Customers

- DNA synthesis and protein solutions
- NGS applications



### MORE Applications


- AI antibody discovery
- Agrigenomics

### MORE Markets

- Protein engineering
- WGS solutions
- GMP



# How Twist Operates Sets Us Apart from Others



# COMPELLING UPSIDE

**Differentiated** platform provides diversified product, innovation


**Growing market share, expanding serviceable** market opportunities

Working with **top companies, landing and expanding accounts**

**Durable** revenue growth, >50% gross margin

Line of sight to adj **EBITDA breakeven**

**NPI powerhouse** paired with operational execution



## LOADING MORE ON THE SAME CHIP

T W I S T  
BIOSCIENCE

**WRITING  
THE FUTURE**

# Adjusted EBITDA Reconciliation

(In Thousands)	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY2025
<b>GAAP Net Income (Loss)</b>	<b>(\$ 139,931)</b>	<b>(\$152,098)</b>	<b>(\$217,863)</b>	<b>(\$204,619)</b>	<b>\$(208,726)</b>	<b>\$(77,670)</b>
<b>Add (Deduct) Adjustments:</b>						
Interest income	( 1,499)	(435)	(3,062)	(14,365)	(15,344)	(11,364)
Interest expense	787	367	80	—	—	—
Income tax expense (benefit)	382	(1,930)	(10,411)	1,153	560	719
Depreciation and amortization	6,677	9,750	16,514	29,310	31,432	24,853
<b>EBITDA</b>	<b>(\$ 133,584)</b>	<b>(\$144,346)</b>	<b>(\$217,742)</b>	<b>(\$188,521)</b>	<b>\$(192,079)</b>	<b>\$(63,462)</b>
<b>Add (Deduct) Adjustments:</b>						
Other income/expense, net	182	1,370	1,087	672	2,679	903
Stock-based compensation expense	17,096	36,998	79,664	30,278	50,925	64,459
Gain on sale of business	—	—	—	—	—	(48,847)
Gain on deconsolidation of business	—	—	(4,607)	—	—	—
Litigation settlement	22,500	—	—	—	—	—
Change in fair value of contingent considerations and holdbacks	—	(534)	(14,245)	(5,912)	—	—
Restructuring costs	—	—	—	9,384	—	—
Impairment of long-lived assets	—	—	—	6,785	44,930	—
<b>Adjusted EBITDA</b>	<b>(\$ 93,806)</b>	<b>(\$106,512)</b>	<b>(\$152,843)</b>	<b>(\$147,314)</b>	<b>\$(93,545)</b>	<b>\$(46,947)</b>

# Adjusted R&D and SG&A Expenses Reconciliation

(In Millions)	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
<b>R&amp;D Expenses — GAAP</b>	<b>\$43.0</b>	<b>\$69.1</b>	<b>\$120.3</b>	<b>\$106.9</b>	<b>\$90.9</b>	<b>\$80.3</b>
<b>Adjusted to exclude:</b>						
Depreciation and Amortization	3.0	3.2	3.5	4.0	3.0	1.3
Stock-based Compensation Expense	3.3	10.2	19.5	13.9	11.2	9.0
<b>Adjusted R&amp;D Expenses</b>	<b>\$36.7</b>	<b>\$55.7</b>	<b>\$97.3</b>	<b>\$88.9</b>	<b>\$76.6</b>	<b>\$70.0</b>
<b>SG&amp;A Expenses — GAAP</b>	<b>\$103.3</b>	<b>\$135.9</b>	<b>\$212.9</b>	<b>\$189.7</b>	<b>\$218.4</b>	<b>\$247.0</b>
<b>Adjusted to exclude:</b>						
Depreciation and Amortization	1.8	3.6	6.5	6.9	6.8	6.5
Stock-based Compensation Expense	12.5	24.2	55.5	11.8	35.7	48.5
<b>Adjusted SG&amp;A Expenses</b>	<b>\$89.0</b>	<b>\$108.2</b>	<b>150.9</b>	<b>\$171.1</b>	<b>\$175.9</b>	<b>\$192.0</b>
<b>Adjusted R&amp;D + SG&amp;A Expenses</b>	<b>\$125.7</b>	<b>\$163.9</b>	<b>248.2</b>	<b>\$260.0</b>	<b>\$252.5</b>	<b>\$262.0</b>